Sunil Badve

Vice Chair/ Professor

Emory University

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Sunil Badve is a Vice Chair and Professor at Emory University in the United States. His research primarily focuses on breast carcinoma, particularly the assessment of Ki-67, the implications of artificial intelligence in digital pathology, and various aspects of triple-negative breast cancers. He has contributed to the field through several recent publications, examining diagnostic criteria, intraoperative assessments, and tumor microenvironment interactions.

Articles (18)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (16)

Yesim Gokmen-Polar

Associate Professor

Emory University

UNITED STATES

Sunil Badve

Research Interests

Explore related searches

Contact this professor

About

Articles (18)

Artificial intelligence in digital pathology — time for a reality check

Bridging cell morphological behaviors and molecular dynamics in multi-modal spatial omics with MorphLink

Analytical Comparison of Commonly Used Laboratory-Developed Tests for the Assessment of Ki-67 in Breast Carcinoma With a Food and Drug Administration–Approved Benchmark

Thymic Rosai-Dorfman Disease: A Rare Presentation With Unusual Histopathologic Features

Malignant phyllodes tumours of the breast: the case for revising WHO’s ‘full house’ diagnostic criteria

Lumpectomy without radiation for ductal carcinoma in situ of the breast: 20-year results from the ECOG-ACRIN E5194 study

Triple Negative Breast Cancers: An Obsolete Entity?

Targeting the Tumor-Tumor Microenvironment Crosstalk

A predictor of response in HER2+ breast cancer—at last!

Predicting Breast Cancer Events in Ductal Carcinoma In Situ (DCIS) Using Generative Adversarial Network Augmented Deep Learning Model

Intraoperative assessment of axillary sentinel lymph nodes by telepathology

Artificial intelligence in breast pathology – dawn of a new era

Dual Prognostic Classification of Triple-Negative Breast Cancer by DNA Damage Immune Response and Homologous Recombination Deficiency

Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer

Beta-2 Adrenergic Receptor Gene Expression in HER2-Positive Early-Stage Breast Cancer Patients: A Post-hoc Analysis of the NCCTG-N9831 (Alliance) Trial

Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study

Tumor Infiltrating Lymphocytes in Multi-National Cohorts of Ductal Carcinoma In Situ (DCIS) of Breast

Determining PD-L1 Status in Patients With Triple-Negative Breast Cancer: Lessons Learned From IMpassion130

Collaborators (16)

Yesim Gokmen-Polar

Adrian Harris

Rafael Caparica

Mauro Giuseppe MASTROPASQUA

Lajos Pusztai

Daniele Generali

Signe Borgquist

Anna Ehinger

Anant Madabhushi

Gulisa Turashvili

Joseph A. Sparano

Balazs Acs

Shane Stecklein

Antonio Wolff

Steven Bray

Linghua Wang

Make your next move.